Teva Incoming CEO Yanai To Take The Helm In First Half 2007
This article was originally published in The Pink Sheet Daily
Teva appoints CEO Makov’s successor, the leader of a generic crop protection chemicals firm, from outside pharma.
You may also be interested in...
Par and Barr will acquire 15 of the companies’ generic offerings.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.
Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4